C. Schär

Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents– a real-world cross-sectional study from Switzerland (SAKK 95/16)

B. Thürlimann, R. Cathomas, P. Bohanes, 2021, BMC cancer.

Validation of the Decipher Genomic Classifier in Patients receiving Salvage Radiotherapy without Hormone Therapy after Radical Prostatectomy - An Ancillary Study of the SAKK 09/10 Randomized Clinical Trial.

D. Zwahlen, G. Hildebrandt, A. Pollack, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)

B. Thürlimann, R. Cathomas, P. Bohanes, 2019, Journal of bone oncology.

Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study.

B. Thürlimann, R. Cathomas, M. Schwenkglenks, 2021, Swiss medical weekly.

Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial.

P. Wust, J. Bernhard, G. Hildebrandt, 2021, European urology.

Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10.

P. Wust, J. Bernhard, G. Hildebrandt, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Erectile function preservation after salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: Five-year results of the SAKK 09/10 randomized phase 3 trial

M. Beck, P. Ghadjar, T. Hölscher, 2024, Clinical and Translational Radiation Oncology.